Clinical Trial: Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07637162) titled 'Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia' on June 04.

Brief Summary: This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.

Study Start Date: April 29

Study Type: INTERVENTIONAL

Condition: Fibromyalgia

Intervention: DRUG: AXS-14 (esreboxetine)

AXS-14 tablets taken twice daily.

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Axsome Therapeutics, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....